The quest for an HIV-1 vaccine--moving forward

Affiliations

¹ From the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston; and the Ragon Institute of Massachusetts General Hospital, the Massachusetts Institute of Technology, and Harvard University, Cambridge, MA.

Dan H Barouch. N Engl J Med. 2013.

. 2013 Nov 28;369(22):2073-6.

doi: 10.1056/NEJMp1312711.

¹ From the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston; and the Ragon Institute of Massachusetts General Hospital, the Massachusetts Institute of Technology, and Harvard University, Cambridge, MA.

No abstract available

References

1. Flynn NM, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. The Journal of infectious diseases. 2005;191:654–665. - PubMed
1. Pitisuttithum P, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. The Journal of infectious diseases. 2006;194:1661–1671. - PubMed
1. Buchbinder SP, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372:1881–1893. - PMC - PubMed
1. Rerks-Ngarm S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361:2209–2220. - PubMed
1. Haynes BF, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012;366:1275–1286. - PMC - PubMed